Core Viewpoint - The company is facing challenges in its financial performance for 2024, with a significant decline in revenue and net profit, primarily due to strategic business adjustments and ongoing project developments [2]. Group 1: Financial Performance - In 2024, the company's operating revenue decreased by 13.89% year-on-year, resulting in a net profit loss [2]. - The decline in revenue and profit is attributed to the active contraction of the construction steel structure business, the ongoing trial production of the Shandong Lingkai project, and increased financial costs due to higher bank financing [2]. Group 2: Market Position and Competitive Advantage - The company has a strong market competitiveness and brand recognition in the pharmaceutical and health beverage sectors, with several products included in the medical insurance catalog [3]. - The company's health business segment, Huashen Blue Light, possesses rare mineral water resources, with its Biri 59 product having a silicate content of 59.99 mg/L, significantly exceeding national standards [3]. Group 3: Research and Development Focus - The company plans to focus on the in-depth exploration and secondary development of major traditional Chinese medicine products, particularly the Sanqi Tongshu capsules and Biyuan Shu, to enhance product application range and efficacy [4]. Group 4: Response to Industry Policy Changes - The company is closely monitoring changes in medical insurance payment reforms and drug procurement policies, aiming to enhance its risk resistance through market expansion and product quality management [5]. Group 5: New Market Expansion - The company is considering international market expansion based on its core traditional Chinese medicine products, which are recognized in the German Pharmacopoeia, while also planning to develop related health products and services [6]. Group 6: Asset Restructuring and Strategic Investment - The company will prudently evaluate asset restructuring and strategic investment opportunities based on its development strategy and market conditions [7].